Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago. Put another way, Precision Biologics is in the right place, at the right time, with the right products.

When our cancer vaccines were tested in human trials in the late 1970s and early 1980s, genetic engineering was in its infancy and the technology was insufficient to isolate and characterize the specific tumor antigens. But marrying our proprietary antibodies with today’s technology has enabled us to identify these tumor-specific targets.